Saved From COVID-19

• Status: Terminated
• Trial end date: 2021-01-07
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Chloroquine

Criteria

Inclusion Criteria:

1. Age ≥18 years,

2. Employment by New York Presbyterian Hospital

3. Clear assignment to areas of the hospital that involve patient contact and possible exposures for at least 2 days a week >/= 8 hours a day

Exclusion Criteria:

1. Individuals who are taking CQ for other indications

2. New use of NSAIDs

3. High risk background medications not limited to immunosuppressive regimens, steroids, anti-B cell therapies, anti-cytokine therapies, chemotherapies, Janus Kinase (JAK)-inhibitors

4. Individuals with a history of retinopathy that would contraindicate the use of CQ

5. Known allergy to CQ or chloroquine

6. Known QT prolongation and torsades de point

7. Individuals who are pregnant or nursing